Solvay Looking to Sell Pharmaceutical Unit

May 2009
Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p8
The article reports on the plan of Solvay Group SA to sell its pharmaceutical unit in the U.S. The "Wall Street Journal" reveals that Solvay has held preliminary discussions with potential buyers including Bayer AG, Sanofi-Aventis SA, and AstraZeneca PLC. It states the success of the company's pharmaceutical division in selling drugs for cholesterol, hypertension, and Parkinson's disease.


Related Articles

  • Healthy trade. Hewitt, Allison // Pharmaceutical Executive;Mar1998, Vol. 18 Issue 3, p116 

    Reports that Sanofi and Bayer AG have concluded an exclusive licensing agreement for Sanofi to acquire marketing rights for the antidiabetic drug Diasabol in all major international markets except North America and Japan.

  • BP to Quit Packaging, Fabrics. Westervelt, Robert // Chemical Week;1/17/2001, Vol. 163 Issue 3, p7 

    Reports on the move of BP Chemicals to sell its packaging and fabric businesses. BP's business agreements with Bayer and Solvay companies; Products produced by the packaging and fabric businesses.

  • Pharmaceuticals Industry Profile: Europe.  // Pharmaceuticals Industry Profile: Europe;Dec2005, p1 

    Presents a profile of the Pharmaceuticals industry in Europe. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pharmaceuticals Industry Profile: Taiwan.  // Pharmaceuticals Industry Profile: Taiwan;Dec2005, p1 

    Presents a profile of the Pharmaceuticals industry in Taiwan. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

  • Sanofi Will Pay $1.9 Bil. For Chattem.  // MMR;1/11/2010, Vol. 27 Issue 1, p85 

    The article reports on the plan of Sanofi-aventis Ltd. to acquire Chattem Inc., a consumer health care company , through a 1.9 billion dollars deal which will expand its presence in the over-the-counter drug market in the U.S.

  • Drug maker announces major expansion of Oro Valley plant.  // Inside Tucson Business;1/2/2006, Vol. 15 Issue 29, p8 

    The article announces the plans of pharmaceutical company Sanofi-Aventis SA to construct a new facility in Tucson, Arizona. It operates a pharmaceutical research center at Oro Valley that employs seventy people. The drug maker is also known as the manufacturer of the anti-clotting medication Plavix.

  • Sanofi-Aventis slashes hundreds of sales rep positions. A. V. // Medical Marketing & Media;Jan2009, Vol. 44 Issue 1, p26 

    The article reports on the plans of Sanofi-Aventis to cut its sales representatives in the U.S. The company plans to reduce its representatives to 10% or less of its 6,500. It attempts to shuffle some of the redundant positions to other areas of the company. It announces that it adheres with...

  • Genfit Renews Collaborations With Sanofi-Aventis, Solvay. Etheridge, James // BioWorld International;2/28/2007, Vol. 12 Issue 9, p3 

    The article reports on the strategic research collaborations which Genfit has renewed with Sanofi-Aventis of Paris, France and Solvay of Brussels, Belgium. Genfit is developing drugs to treat cardiovascular, inflammatory and metabolic diseases. Both collaborations aim to identify and develop new...

  • FDA-APPROVED PROSTATE CANCER TREATMENTS.  // Monthly Prescribing Reference;Fall2013, p165 

    The article offers brief information on several prostate cancer treating drugs that have been approved by the U.S. Food and Drug Administration (FDA) including the Nilandron and the Jevtana from Sanofi-Aventis SA and the AstraZeneca PLC.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics